These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
468 related articles for article (PubMed ID: 32051297)
1. Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial. Wang H; Huang L; Gao P; Zhu Z; Ye W; Ding H; Fang L BMJ Open; 2020 Feb; 10(2):e030738. PubMed ID: 32051297 [TBL] [Abstract][Full Text] [Related]
2. Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer. Shi Y; Wan X; Tan C; Li J; Peng L Adv Ther; 2020 Feb; 37(2):847-859. PubMed ID: 31902066 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With Qin S; Li J; Wang L; Xu J; Cheng Y; Bai Y; Li W; Xu N; Lin LZ; Wu Q; Li Y; Yang J; Pan H; Ouyang X; Qiu W; Wu K; Xiong J; Dai G; Liang H; Hu C; Zhang J; Tao M; Yao Q; Wang J; Chen J; Eggleton SP; Liu T J Clin Oncol; 2018 Oct; 36(30):3031-3039. PubMed ID: 30199311 [TBL] [Abstract][Full Text] [Related]
4. Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England. Tikhonova IA; Huxley N; Snowsill T; Crathorne L; Varley-Campbell J; Napier M; Hoyle M Pharmacoeconomics; 2018 Jul; 36(7):837-851. PubMed ID: 29498000 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of Stintzing S; van Oostrum I; Pescott CP; Ronga P; Heeg B; Heinemann V J Med Econ; 2020 May; 23(5):448-455. PubMed ID: 31903807 [No Abstract] [Full Text] [Related]
6. Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer. Han J; Xiao D; Tan C; Zeng X; Hu H; Zeng S; Jiang Q; She L; Yao L; Li L; Tang L; Ma J; Huang J; Shen L Cancer Control; 2020; 27(1):1073274820902271. PubMed ID: 32107929 [TBL] [Abstract][Full Text] [Related]
7. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation. Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222 [TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer. Bai L; Zhang P; Zhou K; Liao W; Li Q Cancer Manag Res; 2019; 11():10419-10426. PubMed ID: 31849531 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of selective first-line use of biologics for unresectable Wong WWL; Zargar M; Berry SR; Ko YJ; Riesco-Martínez M; Chan KKW Curr Oncol; 2019 Oct; 26(5):e597-e609. PubMed ID: 31708653 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Chu JN; Choi J; Ostvar S; Torchia JA; Reynolds KL; Tramontano A; Gainor JF; Chung DC; Clark JW; Hur C Cancer; 2019 Jan; 125(2):278-289. PubMed ID: 30343509 [TBL] [Abstract][Full Text] [Related]
11. Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Graham CN; Hechmati G; Fakih MG; Knox HN; Maglinte GA; Hjelmgren J; Barber B; Schwartzberg LS J Med Econ; 2015; 18(8):619-28. PubMed ID: 25822327 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Rivera F; Valladares M; Gea S; López-Martínez N J Med Econ; 2017 Jun; 20(6):574-584. PubMed ID: 28107090 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Graham CN; Hechmati G; Hjelmgren J; de Liège F; Lanier J; Knox H; Barber B Eur J Cancer; 2014 Nov; 50(16):2791-801. PubMed ID: 25219451 [TBL] [Abstract][Full Text] [Related]
14. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer. Tumeh JW; Shenoy PJ; Moore SG; Kauh J; Flowers C Am J Clin Oncol; 2009 Feb; 32(1):49-55. PubMed ID: 19194125 [TBL] [Abstract][Full Text] [Related]
15. Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work. Harty G; Jarrett J; Jofre-Bonet M Appl Health Econ Health Policy; 2018 Aug; 16(4):515-525. PubMed ID: 29948926 [TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer. Riesco-Martínez MC; Berry SR; Ko YJ; Mittmann N; Giotis A; Lien K; Wong WW; Chan KK J Oncol Pract; 2016 Jun; 12(6):e710-23. PubMed ID: 27143148 [TBL] [Abstract][Full Text] [Related]
17. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; El-Rayes BF; Flowers CR J Clin Oncol; 2015 Apr; 33(10):1112-8. PubMed ID: 25691669 [TBL] [Abstract][Full Text] [Related]
18. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan. Kashiwa M; Matsushita R Clin Ther; 2020 Jul; 42(7):1361-1375. PubMed ID: 32616433 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994 [TBL] [Abstract][Full Text] [Related]
20. A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US. Graham CN; Christodoulopoulou A; Knox HN; Sabatelli L; Hechmati G; Garawin T; Strickler JH J Med Econ; 2018 Nov; 21(11):1075-1083. PubMed ID: 30091652 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]